Tezepelumab PRO Study

Exclusion Criteria

• •1. Patients who had asthma exacerbation within one month before study enrollment
• •2. Patients who had the biologics treatment in following period prior to the enrollment
• •* omalizumab in 2 or 4 weeks depending on the body weight and total IgE amount
• •* mepolizumab in 4 weeks
• •* Benralizumab in 8 weeks
• •* Dupilumab in 2 weeks
• •3. Patients with cough related diseases other than asthma as determined by treating physicians
• •4. Patients participating in studies that affect this study (study with other interventional treatment to evaluate efficacy/safety of treatment in patients with cough, asthma, or allergic/eosinophilic diseases)
• •5. Any disorder, including heart failure, malignancy, morbid obesity(BMI≧35) , respiratory infectious disease that is not stable (e.g. patients who need medical treatment) in the opinion of the investigator and could:
• •* Affect the safety of the patient throughout the study
• •* Impede the patient's ability to complete the entire duration of study
• •6. Patients with pregnancy or lactation period